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Abstract  
Bacterial infection is a frequent trigger of ACLF, syndrome that could also increase 
the risk of infection. This investigation evaluated: prevalence and characteristics of 
bacterial and fungal infections causing and complicating ACLF; predictors of follow-
up bacterial infections; and impact of bacterial infections on survival.  
Patients: 407 patients with ACLF and 235 patients with acute decompensation (AD).  
Results: 152 patients (37%) presented bacterial infections at ACLF diagnosis; 46% 
(n=117) of the remaining 255 patients with ACLF developed bacterial infections 
during follow-up (4 weeks). The corresponding figures in patients with AD were 25% 
and 18% (p<0.001). Severe infections (SBP, pneumonia, severe sepsis/shock, 
nosocomial infections and infections caused by multi-resistant organisms) were more 
prevalent in patients with ACLF. Patients with ACLF and bacterial infections (either 
at diagnosis or during follow-up) showed higher grade of systemic inflammation at 
diagnosis of the syndrome, worse clinical course (ACLF 2-3 at final assessment: 
47% vs. 26%; p<0.001) and lower 90-day probability of survival (49% vs. 72.5%; 
p<0.001) than patients with ACLF without infection. Bacterial infections were 
independently associated with mortality in patients with ACLF-1 and 2. Fungal 
infections developed in 9 patients with ACLF (2%) and in none with AD, occurred 
mainly after ACLF diagnosis (78%) and had high 90-day mortality (71%). 
Conclusion: Bacterial infections are extremely frequent in ACLF. They are severe 
and associated with intense systemic inflammation, poor clinical course and high 
mortality. Patients with ACLF are highly predisposed to develop bacterial infections 
within a short follow-up period and could benefit from prophylactic strategies. 
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What is already known about this subject? 
Bacterial infections are a frequent precipitating event of ACLF. Type and severity of 
infections have been partially described. Other characteristics of bacterial infections, 
risk of bacterial and fungal infections after ACLF diagnosis, microbiology and 
relationship with clinical course are unknown. 
 
What are the new findings? 
 Patients with ACLF are highly predisposed to develop bacterial infections 
within a short follow-up period. 
 Severe infections (SBP, pneumonia, severe sepsis/shock, nosocomial 
infections and infections caused by multi-resistant organisms) are more 
prevalent in patients with ACLF. 
 Bacteria infections, either at diagnosis or during follow-up, are key prognostic 
determinants in patients with ACLF. They are associated with more severe 
systemic inflammation, poorer clinical course and higher mortality. 
 Bacterial infections are independent predictors of 90-day mortality in patients 
with ACLF 1 and 2. 
 Inappropriate empirical antibiotic strategies increase 90-day mortality in ACLF 
triggered or complicated by infection. 
 
Impact on clinical practice 
- Infection control practices are essential in the management of patients with ACLF. 
- Patients with ACLF may benefit from prophylactic strategies aimed to decrease 
their prohibitive risk of infection. 
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INTRODUCTION 
 
Acute-on-chronic fiver failure (ACLF) in cirrhosis is a syndrome characterized by 
acute decompensation (AD), organ failure(s) and high short-term mortality.1 Bacterial 
infection is the most frequent trigger of ACLF in Western countries.1-3  
Patients with decompensated cirrhosis present chronic systemic inflammation due to 
intestinal dysbiosis, loss of integrity of the intestinal mucosal barrier and sustained 
translocation of pathogen associated molecular patterns (PAMPs).4-7 In patients with 
bacterial infections, ACLF is due to massive release of PAMPs by the infecting 
bacteria. PAMPs activate innate immune system leading to the release of 
inflammatory cytokines, vasodilatory mediators and reactive oxygen species.4,7-9 
Other precipitating events (i.e. acute alcoholic hepatitis; HBV flare) cause systemic 
inflammation by the release of damaged-associated molecular patterns (DAMPs) by 
the liver.10 Multi-organ dysfunction/failure in ACLF develops as consequence of 
acute impairment in systemic circulatory function and organ hypo-perfusion and also 
to direct deleterious effects of inflammatory mediators in organ homeostasis, a 
feature known as immune-pathology.3,4,7, 11 
It has been suggested that in addition to being a trigger of ACLF, bacterial infections 
may also be a specific complication of the syndrome. The hypothesis is that, as it 
occurs in sepsis,1 the exaggerated systemic inflammatory response associated  with 
ACLF may be followed by a state of immune-paralysis that predisposes to early 
development of secondary infections and contributes to increase mortality.12-16 This 
hypothesis is supported by a single study showing a higher prevalence of bacterial 
infections during hospitalization in patients with ACLF (defined according to outdated 
criteria) in comparison to AD.17 Other 2 studies suggest that nosocomial infections 
are independent predictors of ACLF.18,19 Type and severity of infections were 
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partially described in these studies with no mention on other characteristics of 
bacterial infections, microbiology and relationship with clinical course.   
The current study was performed to assess the prevalence of bacterial infections 
triggering and complicating ACLF, the characteristics of these infections and their 
impact on the clinical course and prognosis using information from the Canonic 
database.1 Data on fungal infection and colonization were also analyzed.  
 
PATIENTS AND METHODS 
Study population and aims of the study 
In the current investigation, only patients with complete 4-week follow-up data after 
diagnosis of AD or ACLF were included. We excluded 701 patients, 636 with AD 
without scheduled visits after diagnosis as per protocol and 65 with insufficient data 
at diagnosis (figure 1). Therefore, 642 patients were finally included, 407 with ACLF 
(292 diagnosed at enrolment and 115 during hospitalization) and 235 with AD 
without ACLF. Follow-up visits were performed at days 1, 2, 7, 14, 21 and 28 after 
diagnosis of ACLF or AD. Patients with AD developing ACLF during hospitalization 
completed the 28-day follow-up period after ACLF diagnosis. Data on the 
development of bacterial or fungal infections, including type and site of acquisition, 
clinical characteristics and microbiology, were recorded at diagnosis and at each 
visit.  
 
Definitions related to infection 
Diagnostic criteria of bacterial infections were the following. Spontaneous bacterial 
peritonitis (SBP): polymorphonuclear (PMN) cell count in ascitic fluid ≥250/mm3. 
Urinary tract infection (UTI): abnormal urinary sediment (>10 leukocytes/field) and 
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positive urinary culture or uncountable leukocytes per field if negative cultures. 
Spontaneous bacteremia: positive blood cultures and no cause of bacteremia. 
Secondary bacteremia: a) catheter-related infection (positive blood and catheter 
cultures), b) bacteremia occurring within 24h after an invasive procedure. 
Pneumonia: clinical signs of infection and new infiltrates on chest x-ray. Bronchitis: 
clinical features of infection, no radiographic infiltrates and positive sputum culture. 
Skin and soft tissue infections (SSTI): clinical signs of infection associated with 
swelling, erythema, heat and tenderness in the skin. Cholangitis: cholestasis, right 
upper quadrant pain and/or jaundice and radiological data of biliary obstruction. 
Spontaneous bacterial empyema: PMN count in pleural fluid ≥250/mm³. Secondary 
peritonitis: PMN count in ascitic fluid ≥250/mm³ and evidence (abdominal CT/ 
surgery) of an intraabdominal source of infection. Clostridium difficile infection (CDI): 
positive stool toxin in a patient with diarrhea. Unproved bacterial infection: presence 
of fever and leukocytosis requiring antibiotic therapy without any identifiable 
source.20  
Fungal infections were defined as follows.  Invasive candidiasis: isolation of Candida 
spp in 1 or more blood cultures (candidemia) or from normally sterile body fluids. 
Candida colonization: isolation of Candida spp in non-sterile fluid in the absence of 
infection. Probable invasive aspergillosis (IA): detection of Aspergillus by direct 
examination and/or culture of respiratory samples in the presence of radiological 
imaging compatible with lung infection.21 
Criteria used to define the site of acquisition of infection, infection resolution and 
appropriateness of empirical antibiotic strategies are described in the supplementary 
material section. 
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Bacterial infections were considered as potential triggers of ACLF when they were 
detected prior or at the time of diagnosis of the syndrome (day 0). Infections were 
qualified as complications of ACLF when they were detected between day 1 and day 
28 after the diagnosis of the syndrome. These criteria were based in the foreseeable 
sequence of events of ACLF triggered by bacterial infections. First, infections 
causing ACLF precede the onset of the syndrome and ACLF development frequently 
precedes hospital admission. Second, in the Canonic study there was an additional 
1-day delay between hospital admission, study enrolment and ACLF diagnosis in all 
patients as per protocol design and a delay of two or more additional days in 40% of 
patients for other reasons1. Finally, the Canonic protocol included a complete 
diagnostic work-up of bacterial infections at study enrolment. The same criteria were 
used to qualify bacterial infections in patients with AD without ACLF.   
Supplementary table 1 shows the bacteria and fungi isolated in patients with and 
without ACLF. Criteria used to define multidrug-resistant organism (MDROs) have 
been previously described. 20 
Definitions related to ACLF 
Diagnostic criteria of organ failure was based on the CLIF-C organ failure score.1,2 
ACLF grade 1 (ACLF-1) defines the presence of renal failure alone or of any other 
single organ failure if associated to renal dysfunction and/or cerebral dysfunction. 
ACLF grade 2 and grade 3 (ACLF-2 and 3) define the presence of 2 and 3 to 6 organ 
failures, respectively.1,2 The clinical course of ACLF was defined as good-relatively 
good when the ACLF grade at final assessment was 0 or 1 and severe when it was 2 
or 3.22 
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Assessment of systemic inflammation and of oxidative stress at diagnosis of 
ACLF and AD 
Systemic inflammation was assessed by measuring the plasma levels of five 
inflammatory cytokines involved in innate immune responses8 and systemic oxidative 
stress by the determination of the redox state of human serum albumin.  
Cytokines were measured using a multiplexed bead-based immunoassay on a 
Luminex 100 Bioanalyzer. Non-oxidized (human mercaptalbumin, HMA), and 
reversible and irreversible oxidized (normercaptalbumins HNA1 and HNA2) albumin 
forms in plasma were separated by high performance liquid chromatography and 
detected by fluorescence. Normal values in healthy subjects have been previously 
described.8 
 
Statistical analysis  
Results are presented as frequencies and percentages for categorical variables, 
means and SDs for normally distributed continuous variables and median and 
interquartile range for not normally distributed continuous variables. In univariate 
analyses, Chi-square test was used for categorical variables, Student’s t-test or 
ANOVA for normal continuous variables and Mann-Whitney or Kruskal Wallis test for 
not normally distributed continuous variables. To identify predictors of infection in 
ACLF patients, logistic regression models were carried out. Factors showing a 
clinically and statistically significant association to the outcome in univariate analyses 
were selected for the initial model. The final models were fitted by using a step-wise 
forward method based on Likelihood Ratios with the same significance level (p<0.05) 
for entering and dropping variables. The proportional-hazards model for Competing-
Risks proposed by Fine and Gray23 was used to identify independent predictors of 
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mortality. This model was chosen in order to account for liver transplantation as an 
event ‘competing’ with mortality. In all statistical analyses, significance was set at 
p<0.05. Analyses were done with SPSS (version 23.0; SPSS, Inc. Chicago, IL) and 
SAS (version 9.4; SAS Institute Inc.; Cary, NC) statistical packages. 
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RESULTS 
Overall bacterial infections 
Figure 1 shows the flow chart of patients included (n=642) and excluded (n=701) 
from the study. A total of 360 patients (56%) presented bacterial infections during the 
study. In 211 patients (152 patients with ACLF and 59 with AD) infection was present 
at diagnosis. In the remaining 149 patients, infection was diagnosed during follow-
up. Thirty-one patients with bacterial infections at diagnosis developed new bacterial 
infections during follow-up. Twenty-two patients with ACLF complicated by infection 
developed reinfection (reinfections are not included in the analysis of the results). 
 
Bacterial infections triggering ACLF  
Prevalence and characteristics 
Two hundred and eleven patients (33%) presented bacterial infections at diagnosis 
of ACLF or AD. Prevalence was significantly higher in patients with ACLF (overall 
infections: 37% vs. 25%; proved infections: 33.5% vs. 19%; p< 0.001 each). All types 
of infection except for SSTI, CDI and unproved infections were more frequent in 
patients with ACLF. Differences were significant for pneumonia (7.7% vs. 3%, 
p=0.015) and secondary peritonitis (2.6% vs. 0%, p=0.009) (Table 1). The 
prevalence of infections at ACLF diagnosis was significantly higher (p=0.016) in 
patients with ACLF-3 (52%; Supplementary table 2).    
Progression to severe sepsis/septic shock was more frequently observed in 
infections present at diagnosis of ACLF than in those associated with AD (49% vs. 
2%; p<0.001). Prevalence of nosocomial infections (53% vs. 22%; p<0.001) and of 
infections caused by MDROs (16% vs. 3%: p=0.01) was also significantly higher in 
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ACLF (Table 1). Significant differences were also observed when the analysis was 
restricted to patients with ACLF diagnosed at enrolment (data not shown).  
 
Impact of infection on the severity of ACLF, clinical course and mortality  
The grade of systemic inflammation (WBC count, serum CRP levels and plasma 
concentration of inflammatory cytokines) was more intense in patients with infections 
at ACLF diagnosis than in those without (Table 2). Severity of the syndrome was 
also higher in patients with ACLF precipitated by bacterial infections, as indicated by 
a higher prevalence of encephalopathy, circulatory, respiratory and cerebral failure at 
diagnosis of the syndrome, a higher baseline CLIF-C ACLF score, and higher 
requirements of organ support during hospitalization (Table 2). Similar results were 
observed when patients with unproved infections were considered as non-infected 
(Supplementary Table 3). 
The clinical course of ACLF, as estimated by the final ACLF grade, was also 
significantly worse in patients with ACLF caused by bacterial infections. Twenty-eight 
day and 90-day mortality rates were also higher in patients with ACLF triggered by 
bacterial infection (overall or proved episodes), differences being statistically 
significant only at 90 days (Table 2, Supplementary Table 3). 
In order to confirm that infection-triggered ACLF portends a worse prognosis, we 
examined data on the 115 patients with AD who developed ACLF during follow-up. 
Cases triggered by infection showed higher organ support requirements, worse 
clinical course of ACLF and higher 28 and 90-day mortality rates than those caused 
by other precipitating events (Supplementary Table 4). 
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Infection resolution and patient mortality according to the type and characteristics of 
bacterial infections detected at ACLF diagnosis. 
The resolution rate of bacterial infections detected at diagnosis was significantly 
lower in patients with ACLF than in those with AD (71.1% vs. 98.3%; p<0.001). Type 
of infection influenced infection resolution and mortality (Table 3). SSTI and 
unproved infections showed the lowest resolution rates and SSTI and SBP the 
highest mortality rates. The presence of severe sepsis/septic shock and the isolation 
of MDROs also influenced negatively infection resolution and prognosis.   
 
Bacterial infections complicating ACLF not triggered by infection 
Incidence and characteristics  
Patients with ACLF not triggered by infections presented significantly higher 
incidence of bacterial infection during follow-up than patients with AD (46% vs. 18%, 
p<0.001) (Table 1). This feature was observed throughout the entire 28-day follow-
up period (Figure 2A). The risk of developing bacterial infections correlated directly 
with the grade of ACLF (Figure 2B and supplementary table 2). Similar results were 
observed when patients with unproved infections were considered as non-infected 
(Supplementary Figures 1A and 1B).   
All types of bacterial infections were more frequent in patients with ACLF than in 
patients with AD except for CDI (Table 1). Differences were statistically significant for 
pneumonia (8.6% vs. 1.7%, p<0.001), SBP (8.6% vs. 3.4%, p=0.03) and bacteremia 
(3.9% vs. 0.6%, p=0.03). Follow-up infections were also more severe in patients with 
ACLF as indicated by the higher prevalence of sepsis and severe sepsis/septic 
shock (41.9% vs. 6.2%, p< 0.001) and of infections caused by MDROs (18.8% vs. 
3.1%, p=0.02) (Table 1).   
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Risk factors of follow-up bacterial infections in ACLF and impact of infection on 
clinical course and mortality  
Patients with ACLF developing bacterial infections during follow-up were those with 
higher grade of systemic inflammation and higher severity of ACLF at diagnosis as 
indicated by higher WBC count and higher plasma levels of CRP and cytokines, 
higher frequency of hepatic encephalopathy, cerebral and respiratory failure and 
mechanical ventilation, and higher CLIF-C ACLF score. They also presented worse 
clinical course and higher 28-day and 90-day mortality rates (Table 2).   
Supplementary figure 2 shows the individual plasma concentrations of cytokines 
measured at diagnosis of the syndrome in patients with ACLF triggered by infection, 
ACLF complicated by infection and ACLF without infections during the whole study 
period. Although concentrations were higher in infected patients a marked overlap 
among groups was observed. 
Multiple regression analysis identified CLIF-C ACLF score (n=167; OR=1.10, 95% 
CI=1.01-1.08; p=0.017) and HNA2 (n=68; OR=1.15, 95% CI=1.04-1.27; p<0.005) at 
diagnosis as independent risk factors of follow-up bacterial infections. 
The resolution rate of follow-up bacterial infections in patients with ACLF was 78.6% 
vs. 98.8% in AD (Table 3, p<0.001). Resolution rate and mortality rates associated 
with bacterial infections at follow-up were not significantly influenced by the type and 
severity of the infections.  
 
Rate and characteristics of bacterial infections occurring in ACLF according to 
the precipitating event and the need for critical care 
Rate and characteristics of bacterial infections that triggered or complicated ACLF 
differed between patients hospitalized in the ICU and those admitted to the regular 
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ward. In contrast, type of precipitating event did not influence these parameters 
(Supplementary Table 5 and 6). Prevalence of infection was significantly higher in 
patients with ACLF triggered by infection requiring ICU admission. Pneumonia was 
more prevalent in critical care while UTI and SSTI were more frequent in the regular 
ward. As expected, severity of infection was higher in the ICU.  
 
Overall impact of bacterial infections on clinical course and survival in 
patients with ACLF 
The clinical course (ACLF 2-3 at final assessment: 47% vs. 26%; p<0.001) was 
significantly worse and the probability of 90-d transplant-free survival significantly 
shorter (Figure 3A) in patients with ACLF and bacterial infection (either at diagnosis 
or during follow-up) than in those without (45% vs. 70%, p<0.001). Similar results 
were obtained when only patients developing proved infections were considered as 
infected (Supplementary Figure 3). Infections had a great impact on the prognosis of 
patients with the less severe forms of ACLF (Figures 3B and 3C). Infected patients 
with ACLF-1 and ACLF-2 showed a lower 90-d probability of survival than those 
without infection. In contrast, patients with ACLF-3 with and without infections did not 
show differences in prognosis. Patients with AD with and without bacterial infections 
(overall, Figure 3A, and proved, Supplementary Figure 3) also showed a similar 
prognosis, since patients with AD developing ACLF during hospitalization were 
included in the ACLF group.  
Appropriateness of empirical antibiotic strategies also had an impact on clinical 
course and survival of patients with ACLF. Appropriate empirical antibiotic therapy 
was administered in 74% and 72% of bacterial infections triggering and complicating 
ACLF, respectively. Adequacy of initial antibiotic strategies was associated with 
18 
 
lower critical care requirements, better evolution of the syndrome in infection-
triggered ACLF and lower 28 and 90-d mortality (Table 4).  
 
Predictors of mortality 
Supplementary Table 7 shows factors associated with 90-day transplant-free 
mortality in the univariate and multivariate analysis in the whole series of patients 
with ACLF. Age (HR: 1.03), hepatic encephalopathy (HR: 1.98), serum bilirubin (HR: 
1.03), INR (HR: 1.38) and serum creatinine (HR: 1.27) at diagnosis of the syndrome 
were identified as independent predictors of death. When the analysis was restricted 
to patients with ACLF-1 and 2 (Table 5, first model), serum bilirubin (HR: 1.03; 95% 
CI: 1.01-1.05; p<0.001), age (HR: 1.03; 95% CI: 1.00-1.05; p=0.02), bacterial 
infection at diagnosis or during follow-up (HR: 1.79; 95% CI: 1.08-2.96; p=0.02) and 
serum creatinine (HR: 1.14; 95% CI: 1.01-1.29; p=0.04) were identified as 
independent predictors. When appropriateness of initial antibiotic therapy was 
introduced in the model (Table 5, second model), this factor but not bacterial 
infection remained as independent predictor of survival in patients with ACLF-1 and 
2 (HR: 0.40; 95% CI: 0.26-0.63; p<0.001). WBC count and mechanical ventilation 
were not entered in the regression models because of their potential collinearity with 
infection.   
 
Fungal infection and colonization 
Fungal isolation was infrequent and mainly observed in patients with ACLF (3.9% vs. 
0.4%, p=0.005). Of the 16 patients with ACLF and fungal isolation, seven 
corresponded to invasive candidiasis (5 candidemias and 2 secondary peritonitis), 
one to probable IA and 8 to colonization by candida. The single isolation in patients 
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with AD consisted of a urinary colonization by Candida. Six out of the eight invasive 
fungal infections were diagnosed during follow-up in patients with ACLF. In the 
remaining two patients (a secondary peritonitis and an IA) diagnosis was performed 
at ACLF diagnosis. Only nineteen patients (6 of them with candida colonization) 
received antifungal prophylaxis. Mortality rates associated with invasive fungal 
infection and colonization were 57% and 44% at 28-day and 71% and 67% at 90-
day, respectively. 
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DISCUSSION 
The results of our study indicate that bacterial infection is a major problem and a key 
prognostic determinant in ACLF. The overall prevalence of infections in patients with 
ACLF was extremely high (66.1%). Two-thirds of ACLF patients presented infections 
at diagnosis or within follow-up. In contrast, the overall prevalence of infection in 
patients with AD was of 38.7%. The severity of bacterial infections, as indicated by 
the frequency of SBP, pneumonia, severe sepsis, nosocomial infections and 
infections caused by MDROs, was also significantly higher in patients with ACLF. 
Not surprisingly, the clinical course of ACLF, as estimated by the percentage of 
patients with ACLF grade 2 or 3 at final assessment, was significantly worse in 
patients with bacterial infections than in those without (45% vs. 25%). 
The prevalence of bacterial infections at ACLF diagnosis in our series was 37.3%. 
These infections are important because they promote a burst of systemic 
inflammation that precipitates the development of the syndrome.1,3,7 In the current 
study we compared for the first time the severity of ACLF triggered by bacterial 
infections and by other precipitating events. Our results clearly show a greater 
severity of systemic inflammation and of ACLF in patients with infections. The clinical 
course of ACLF was also significantly worse in these patients.  
One of the most outstanding findings of our study was the extremely high incidence 
of follow-up bacterial infections (46%) observed in the 255 patients without infections 
at ACLF diagnosis. This represents that approximately one every two non-infected 
patients with ACLF will develop bacterial infections within 4 weeks after diagnosis. 
This figure contrasts sharply with the 18% incidence of follow-up infections in non-
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infected patients with AD. Bacterial infections are, therefore, not only a frequent 
trigger of ACLF but also an extremely common complication of the syndrome.  
The mechanism of this high risk of follow-up bacterial infections in patients with 
ACLF is likely multifactorial. Severity of systemic oxidative stress (HNA2 levels) and 
of ACLF (CLIF-C ACLF score) at diagnosis were significantly associated with the 
development of follow-up bacterial infections in the current study. Systemic 
inflammation may increase bacterial translocation either directly 24 or indirectly (by 
increasing circulatory dysfunction and homeostatic stimulation of sympathetic 
nervous system). The secondary release of norepinephrine at the intestinal mucosa 
impairs the local immune system function and induces qualitative and quantitative 
changes of the intestinal microbiota towards a phenotype associated with bacterial 
translocation.25 The reduction of the amount of bile acid secretion secondary to liver 
failure is another factor favoring intestinal bacterial overgrowth.26 Finally, the frequent 
instrumentation of patients with cerebral, respiratory or renal failure with intravenous, 
intra-arterial and urinary catheters and the frequent use of artificial organ support 
devices are other major factors increasing the rate of follow-up bacterial infections in 
these patients.27,28 In fact, the more prevalent infections complicating ACLF were 
spontaneous bacteremia and spontaneous bacterial peritonitis, which are caused by 
bacterial translocation, and pneumonia and secondary bacteremia, which are 
commonly observed in patients undergoing invasive therapeutic procedures.  
There are many similarities between ACLF and severe sepsis. Both conditions 
develop in the setting of intense systemic inflammation and oxidative stress. In 
patients with sepsis, systemic inflammation is initiated by an acute release of 
PAMPS by bacteria and secondary activation of the innate immune system cells.29-32 
Approximately 40% of patients with ACLF share this pathophysiological 
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mechanism.1,8,33,34 The second similarity is that patients with ACLF and with severe 
sepsis develop organ failure(s) and that this correlates closely with prognosis.1,19,32,35 
Finally, our study suggests that the third feature shared by patients with ACLF and 
with severe sepsis is that they both are highly predisposed to develop bacterial 
infections shortly after diagnosis. There are many evidences supporting a two-phase 
immune response in patients with severe sepsis.36-39 Following a short initial period 
(few days after diagnosis) of severe systemic inflammation patients develop a 
second period of immune-suppression due to impairment of immune cell function 
and apoptotic depletion of immune cells.39 During this period, aggravation of the 
primary infection or development of new secondary infections is common.40 
The 117 non-infected patients with ACLF at diagnosis of the syndrome represent a 
unique population to assess if this sequence of events also occurs in ACLF, since in 
this group of patients the temporal relationship between systemic inflammation, 
ACLF development and follow-up bacterial infections is not interfered by antibiotic 
therapy. Our results support a two-phase clinical course in non-infected patients with 
ACLF. The first-phase, probably very short, is characterized by acute development of 
severe systemic inflammation and organ/system failure(s). ACLF is diagnosed at the 
end of this phase. The second-phase, of longer duration, is characterized by a 
remarkable high incidence of bacterial infections that mainly develop within the first 
week after the diagnosis of ACLF. Whether immune-suppression is involved in the 
pathogenesis of this second phase is currently unknown, but impaired pathogen 
killing activity and reactive oxygen species release by macrophages and neutrophils 
has been reported in these patients.41,42 Recent studies have also shown that 
patients with ACLF have increased numbers of immunoregulatory monocytes and 
macrophages that express MERTK and elevated plasma levels of prostaglandin E2, 
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alterations that suppress the innate immune response to microbes and could 
increase the risk of infection. 43,44 
The high incidence of bacterial infection after ACLF diagnosis justifies the 
implementation of infection control practices such as bundles on prevention of 
ventilator-associated pneumonia and catheter-related bacteremia and hand 
hygiene.45 Selective intestinal decontamination with non-absorbable antibiotics could 
also prevent nosocomial infections in ACLF patients but could also promote the 
development of MDROs.46,47 Treatments aimed at restoring the patients' immune 
function could also be beneficial in these patients.48,49 Our study also demonstrates 
that adequacy of empirical antibiotic strategies is also a key factor in the 
management of infected patients with ACLF. Inappropriate first line therapies were 
associated with increased mortality. Therefore, broad antibiotic schemes covering all 
potential pathogens should be applied at high doses within the first 48-72h after the 
diagnosis of infection to improve clinical efficacy and minimize the selection of 
resistant strains.45  
We observed significantly higher mortality rate and shorter probability of survival in 
patients with ACLF triggered or complicated by bacterial infections than in patients 
with ACLF without bacterial infections throughout the entire period of observation, 
suggesting that bacterial infections has a major impact on the prognosis of patients 
with ACLF. This is also supported by the observation that infection was an 
independent predictor of mortality in patients with ACLF grade 1 and 2. The overall 
prevalence of bacterial infections in patients ACLF-3 was so high (91%) that they did 
not impact prognosis.   
The prevalence of fungal infections in our patients with ACLF was low (2%) and 
mainly occurred during the follow-up period after ACLF diagnosis. This figure is in 
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line with recent studies showing a low incidence of invasive fungal infections in 
patients with cirrhosis admitted to ICU (1%).50 However, fungal infections could have 
been under-estimated in our study since specific cultures were not performed. The 
relatively low rate of patients with ACLF-3 included in the Canonic series (20%) 
could also explain this finding. 
In summary, bacterial infections are a significant problem and a major prognostic 
determinant in patients with ACLF. Infections are detected at ACLF diagnosis in one-
third of the patients. Among the remaining patients with ACLF, approximately half 
develop bacterial infections within a follow-up period 4-week. The severity of 
systemic inflammation and of ACLF is significantly higher, the clinical course 
significantly worse and mortality significantly higher in patients with ACLF and 
bacterial infections than in those without. Adequate empirical antibiotic strategies, 
infection control practices and prophylactic measures are essential in the 
management of patients with ACLF. 
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 FIGURE LEGENDS 
Figure 1  
Flow chart of the patients included and excluded from the study. In total, 642 patients 
were included. Three hundred sixty patients developed infections throughout the 
study: 152 with ACLF and 59 with AD presented an infection at diagnosis, 149 
patients without infections at diagnosis developed infections during follow-up (117 
with ACLF and 32 with AD). Finally, 53 patients with bacterial infections at diagnosis 
or during follow-up developed new bacterial infections. 
  
Figure 2A 
Probability of developing bacterial infections during follow-up in patients with ACLF 
(red line) and AD (green line) without infections at diagnosis. Probability was 
significantly higher in patients with ACLF, especially in the first week after diagnosis. 
 
Figure 2B 
Incidence of bacterial infections within follow-up in patients with AD and with ACLF-
1, ACLF-2 and ACLF-3 without bacterial infections at diagnosis. Incidence correlated 
with the grade of ACLF, being extremely high in patients with ACLF-3. 
 
Figure 3A 
Probability of 90-day transplant-free survival in patients with AD and ACLF with and 
without bacterial infections. Survival was significantly shorter (p<0.001) in patients 
with ACLF and bacterial infections [either at diagnosis (ACLF-BiD) or during follow-
up (ACLF-BiFu); continuous red and orange lines, respectively] than in patients with 
26 
 
ACLF without bacterial infections (discontinuous red line; ACLF-NoBi) and in patients 
with AD with (continuous green line; AD-Bi) and without bacterial infections 
(discontinuous green line; AD-NoBi). 
 
Figure 3B 
Probability of 90-d transplant-free survival in patients with ACLF-1 (green), ACLF-2 
(blue) and ACLF-3 (red) with (continuous lines) and without (discontinued lines) 
bacterial infections (either at diagnosis or during follow-up). Patients with ACLF 1 
and ACLF-2 without bacterial infections showed a higher probability of survival than 
those with infection (p=0.004 and p=0.024, respectively).  
 
Figure 3C 
90-d mortality rate of patients with ACLF 1-2 and with ACLF-3 with (red) and without 
(blue) bacterial infections (either at admission or during follow-up). Difference was 
statistically significant in patients with ACLF 1-2 (p<0.001) but not in patients with 
ACLF-3. 
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Table 1. Prevalence and characteristics of bacterial infections present at diagnosis or developed during 
 follow-up and associated mortality in patients with AD and ACLF 
 At diagnosis* During follow-up** 
     AD 
(n=235) 
  ACLF 
(n=407) 
   AD 
(n=176) 
  ACLF 
(n=255) 
Prevalence and types of infection 
Prevalence of infections (n/%) 59(25.1) 152(37.3)*** 32(18.2) 117(45.9)*** 
Types of infection (n/%)     
Spontaneous bacterial peritonitis 16(6.8)  41(9.8) 6(3.4) 22(8.6)* 
Urinary infections 10(4.3) 25(6.0) 12(6.8) 27(10.6) 
Pneumonia   7(3.0) 32(7.7)*  3(1.7) 22(8.6)*** 
Unproved infections 14(6.0) 16(3.8) 7(4.0) 18(7.0) 
SSTI   7(3.0) 12(2.9) 1(0.6)  7(2.7) 
Spontaneous/secondary bacteraemia   1(0.4)   9(2.2) 1(0.6) 10(3.9)* 
Secondary bacterial peritonitis         - 11(2.6)**     - 2(0.8) 
Other1    3(1.3)  6(1.4) 1(0.6) 8(3.1) 
Clostridium difficile infection    1(0.4)       - 1(0.6) 1(0.4) 
Characteristics of bacterial infections 
Site of acquisition (n/%)     
Community-acquired 32(54.2)  38(25.0)***       -        - 
Healthcare-associated 14(23.7)   34(22.4)       -        - 
Nosocomial 13(22.0)   80(52.6) 32(100.0) 117(100.0) 
Infections caused by MDROs (n/%)     
No 57(96.6) 128(84.2)* 31(96.9) 95(81.2)* 
Yes 2(3.4)   24(15.8)   1(3.1) 22(18.8) 
Sepsis (n/%)     
No sepsis 46(78.0) 78(51.3)*** 30(93.8) 68(58.1)*** 
Sepsis 12(20.3) - 1(3.1) 26(22.2) 
Severe sepsis or shock   1(1.7) 74(48.7) 1(3.1) 23(19.7) 
Mortality (n/%)     
28-day mortality 1(1.7) 54(35.5)*** 2(6.3) 45(38.5)*** 
90-day mortality 6(10.2) 77(50.7)*** 3(9.4) 60(51.3)*** 
*All patients included 
**Only patients without bacterial infections at diagnosis 
SSTI Skin and soft tissue infections ; MDROs: Multidrug resistant organisms 
1 Other infections at diagnosis of ACLF: tracheobronchitis (4), spontaneous bacterial empyema (n=1), cholangitis (1),undefined (3). Other infections during follow-up: 
dental infection (1), undefined (8) 
*p-value<0.05; **p-value<0.01; ***p-value<0.001
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Table 2. Clinical and laboratory data at ACLF diagnosis, clinical course, and mortality in patients with and without bacterial infection at 
diagnosis or during follow-up# 
 
Bacterial 
infection at 
ACLF diagnosis 
(n=152) 
No bacterial 
infection at ACLF 
diagnosis 
 (n=255) 
Bacterial infection 
during follow-up## 
(n=117) 
No bacterial infection 
during follow-up## 
 (n=138) 
Cause of admission 
    GI bleeding 
    Infection 
    Encephalopathy 
    HRS 
    Ascites 
    Other 
 
7(8.3) 
31(36.9) 
10(11.9) 
2(2.4) 
19(22.6) 
15(17.9) 
 
26(19.7)* 
25(18.9)** 
33(25.0)* 
7(5.3) 
27(20.5) 
14(10.6) 
 
14(21.2) 
16(24.2) 
20(30.3) 
2(3.0) 
9(13.6) 
5(7.6) 
 
12(18.2) 
9(13.6) 
13(19.7) 
5(7.6) 
18(27.3) 
9(13.6) 
 Clinical and laboratory data  
     Age (years) 
     Alcoholic cirrhosis (%) 
     No prior decompensation (%) 
     Ascites with surrogates (%)  
     Encephalopathy (%) 
     WBC (x109/L) 
     Serum CRP (mg/L) 
     Serum bilirubin (mg/dL) 
     INR 
     Serum creatinine (mg/dL) 
     Plasma sodium (mEq/L) 
     Serum albumin 
     Renal failure (%) 
     Cerebral failure (%) 
     Respiratory failure (%) 
     Circulatory failure (%) 
     Coagulation failure (%) 
     Liver failure (%) 
     MELD score 
     CLIF-C ACLF score 
     NASCELD criteria for ACLF$ 
     ACLF-1(%) 
     ACLF-2(%) 
     ACLF-3(%) 
 
56±13 
80(53.7) 
43(29.7) 
147(96.7) 
83(61.0) 
9.9(6.1-15.4) 
36(21- 77) 
6.8(3.3-14.6) 
1.9(1.5-2.7) 
1.7(1.0-2.6) 
134±7 
2.8(2.4-3.2) 
72(52.2) 
42(30.9) 
25(20.5) 
45(34.1) 
52(39.1) 
48(35.0) 
28±7 
54±11 
22(14.5) 
71(46.7) 
52(34.2) 
29(19.1) 
 
56±11 
148(61.4) 
53(22.3) 
252(98.8) 
111(50.2)* 
6.8(4.6-11.7)*** 
25(11-46)*** 
8.5(2.6-19.4) 
1.9(1.4-2.6) 
1.9(1.0-2.6) 
135±6 
2.9(2.5-3.4) 
112(50.9) 
38(17.2)** 
18(10.2)* 
39(18.0)*** 
65(30.5) 
93(42.9) 
27±7 
48±9** 
22(8.6) 
133(52.2) 
95(37.3) 
27(10.6) 
 
54±11 
63(57.8) 
25(22.3) 
116(99.2) 
62(60.8) 
7.5(5.0-13.2) 
29(16-51) 
11.0(2.7-22) 
2.0(1.5-2.5) 
1.9(1.1-3.0) 
135±6 
2.9(2.6-3.3) 
52(51.5) 
24(23.3) 
13(15.7) 
22(22.2) 
27(27.6) 
46(46.0) 
28±7 
50±9 
17(14.5) 
50(42.7) 
45(38.5) 
22(18.8) 
 
57±11* 
85(64.4) 
28(22.2) 
136(98.6) 
49(41.2)** 
6.5(4.6-9.9)* 
19(9-40)* 
6.6(2.5-16.5) 
1.8(1.4-2.6) 
1.8(0.9-2.4) 
134±6 
2.9(2.5-3.5) 
60(50.4) 
14(11.9)* 
5(5.4)* 
17(14.4) 
38(33.0) 
47(40.2) 
27±7 
46±9* 
5(3.6)** 
83(60.1)*** 
50(36.2) 
5(3.6) 
Inflammatory cytokines  
  TNF (pg/ml) 
  IL-6 (pg/ml) 
  IL-8 (pg/ml) 
  IL-10 (pg/ml) 
  IL-1ra (pg/ml) 
 
37(26-50) 
101(34-466) 
117(66-225) 
18(7-58) 
39(14-108) 
 
29(17-39)** 
29(13-75)*** 
75(38-165)** 
6(2-19)*** 
16(8-42)** 
 
31(18-42) 
33(16-100) 
87(45-165) 
7(3-34) 
23(9-57) 
 
25(15-35)* 
26(11-43)* 
60(32-169) 
4(1-14)** 
14(7-30)* 
Albumin oxidation fractions& 
  HMA (%) 
  HNA1+HNA2 (%) 
  HNA2 (%) 
 
42(30-58) 
56(42-68) 
11(8-15) 
 
46(34-58) 
52(41-64) 
11(6-15) 
 
42(33-58) 
51(41-65) 
12(7-17) 
 
48(35-56) 
52(43-64) 
8(5-12)* 
Need for critical care (28-d) 
    ICU 
    Mechanical ventilation 
    Renal replacement therapy 
    NASCELD criteria for ACLF$ 
 
95(62.5) 
58(38.2) 
51(33.6)  
63(41.5) 
 
112(43.9)*** 
56(22.0)*** 
55(21.6)** 
63(24.7)*** 
 
66(56.4) 
41(35.0) 
31(26.5) 
46(39.3) 
 
46(33.3)*** 
15(10.9)*** 
24(17.4) 
17(12.3)*** 
Clinical course of ACLF 
  No ACLF or ACLF-1 at final assessment 
  ACLF 2-3 at final assessment 
 
74(51.0) 
71(49.0) 
 
151(64.8)** 
82(35.2) 
 
61(54.5) 
51(45.5) 
 
90(74.4)** 
31(25.6) 
28-day transplant free mortality 54(35.5) 71(27.8) 45(38.5) 26(18.8)*** 
90-day transplant free mortality 77(50.7) 98(38.4)* 60(51.3) 38(27.5)*** 
# Patients are divided in two groups: A: patients with and without bacterial infections at diagnosis of ACLF, B: patients with ACLF without bacterial 
infections at diagnosis who did and did not develop bacterial infections during follow-up. 
## Patients with ACLF and bacterial infection at diagnosis of the syndrome were excluded from this analysis 
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$: two or more of the following: vasopressors, renal replacement therapy, mechanical ventilation, grade 3-4 hepatic encephalopathy 
& According to the redox state at cysteine 34 
*P-value<0.05; **P-value<0.01; ***P-value<0.001 
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Table 3. Type and characteristics of bacterial infections at ACLF diagnosis or during follow-up: relationship with infection resolution and patient mortality 
  Patients with bacterial infections at ACLF diagnosis  Patients with bacterial infections during follow-up 
 N Resolution 
Rate 
Mortality at 
28 days 
Mortality at 90 
days 
 N Resolution 
Rate 
Mortality at 
28 days 
Mortality at 
90 days 
Prevalence and types of infection      117 92(78.6) 45(38.5) 60(51.3) 
Prevalence of bacterial infections (n/%)                         152        108(71.1)            54(35.5)                77(50.7)                            117          92(78.6)           45(38.5)             60(51.3) 
 
         
Type of Infections (n/%) 
Spontaneous bacterial peritonitis 
 
41 
 
26(63.4)** 
 
19(46.3) 
 
24(58.5)* 
  
22 
 
16(72.7) 
 
10(45.5) 
 
13(59.1)   
 
Urinary infections 25 24(96.0) 5(20.0) 11(44.0)  27 23(85.2) 8(29.6) 11(40.7)  
Pneumonia 32 20(62.5) 12(37.5) 18(56.3)  22 15(68.2) 12(54.6) 14(63.6)  
Unproved infections 16 9(56.3) 7(43.8) 8(50.0)  18 16(88.9) 11(61.1) 12(66.7)  
SSTI 12 6(50.0) 7(58.3) 9(75.0)  7 6(85.7) 0(0.0) 1(14.3)  
Spontaneous/secondary bacteraemia 9 7(77.8) 2(22.2) 3(33.3)  10 8(80.0) 2(20.0)  5(50.0)  
Secondary bacterial peritonitis 11 10(90.9) 2(18.2) 4(36.5)  2 0(0.0) 1(50.0)     2(100.0)  
Other1 6 6(100.0) 0(0.0) 0(0.0)  8 7(87.5) 1(12.5)   2(25.0)  
Clostridium difficile infection 0 - - -  1 1(100.0) 0(0.0) 0(0.0)  
            
Characteristics of bacterial infection         
Site of acquisition (n/%)         
Community-acquired 38 27(71.1) 15(39.5) 16(42.1)  - -   
Healthcare-associated 34 20(58.8) 14(41.2) 19(55.9)  - -   
Nosocomial 80 61(76.3) 25(31.3) 42(52.5)  117 92(78.6) 45(38.5) 60(51.3) 
         
Multiresistant bacterial infection (n/%)         
No 128 94(73.4) 43(33.6) 60(46.9)*  95 77(81.1) 36(37.9) 47(49.5) 
Yes 24 14(58.3) 11(45.8) 17(70.8)  22 15(68.2) 9(40.9) 13(59.1) 
         
Severity of infection (n/%)         
No sepsis 78 63(80.8)** 23(29.5) 37(47.4)  68 51(75.0) 23(33.8) 31(45.6) 
Sepsis 0 0(0.0) 0(0.0) 0(0.0)  26 20(76.9) 10(38.5) 15(57.7) 
Severe sepsis or shock 74 45(60.8) 31(41.9) 40(54.1)  23 15(65.2) 12(52.2) 14(60.9) 
SSTI Skin and soft tissue infections 1 Other infections at diagnosis of ACLF: tracheobronchitis (4), spontaneous bacterial empyema (n=1), cholangitis (1), undefined (3).  
Other infections during follow-up: dental infection (1), undefined (8) 
*p-value<0.05; **p-value<0.01; ***p-value<0.001 
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Table 4. Clinical course and mortality of patients with ACLF triggered or complicated by infection receiving appropriate or inappropriate empirical antibiotic 
treatment# 
 Bacterial infection at ACLF diagnosis (n=152) Bacterial infection during follow-up## (n=117) 
 
Inappropriate empirical 
antibiotic treatment  
(n=35) 
Appropriate empirical 
antibiotic treatment  
 (n=112) 
Inappropriate 
empirical antibiotic 
treatment  
(n=24) 
Appropriate empirical 
antibiotic treatment  
 (n=84) 
ICU admission and organ support     
    ICU 
    Mechanical ventilation 
    Renal replacement therapy 
26(74.3) 
17(48.6) 
15(42.9) 
68(60.7) 
40(35.7) 
35(31.3) 
18(75.0) 
10(41.7) 
7(29.2) 
42(50.0)* 
28(33.3) 
20(23.8) 
ACLF evolution 
  No ACLF or ACLF-1 at final assessment 
  ACLF 2-3 at final assessment 
 
12(35.3) 
22(64.7) 
 
59(55.1)* 
48(44.9) 
 
12(54.6) 
10(45.4) 
 
47(57.3) 
35(42.7) 
28-day transplant free mortality 19(54.3) 32(28.6)** 11(45.8) 26(31.0) 
90-day transplant free mortality 26(74.3) 47(42.0)*** 16(66.7) 36(42.9)* 
 
# According to microbiological results or the need for escalation of initial antibiotic treatments in culture negative infections. Data on empirical antibiotic therapy were not 
available in 14 patients. 
## Patients with ACLF and bacterial infection at diagnosis of the syndrome were excluded from this analysis 
*P-value<0.05; **P-value<0.01; ***P-value<0.001 
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Table 5. Predictors of 90-day mortality in the univariate and multivariate analysis in patients with ACLF 1 and ACLF 2. 
  
Model 1. Without considering appropriateness of empirical antibiotic therapy 
 Univariate Analysis  Multivariate analysis# 
Predictors HR (CI 95%) p-value  HR (CI 95%) p-value 
Infection (at ACLF diagnosis or during follow-up)    
Age (years) 
Encephalopathy (%)* 
Leukocytes (x109/L)* 
Bilirubin (mg/dL)* 
INR* 
Creatinine (mg/dL)* 
Heart rate (b.p.m)* 
Mechanical ventilation** 
Renal replacement therapy** 
1.65(1.05-2.60) 
1.01(0.99-1.03) 
1.56(1.03-2.37) 
1.07(1.04-1.11) 
1.02(1.01-1.04) 
1.11(0.91-1.36) 
1.12(0.98-1.28) 
1.02(1.01-1.03) 
2.55(1.62-4.01) 
2.32(1.51-3.57) 
0.031 
0.147 
0.036 
<0.001 
0.007 
0.299 
0.098 
0.001 
<0.001 
<0.001 
 1.79(1.08-2.96) 
1.03(1.00-1.05) 
- 
- 
1.03(1.01-1.05) 
- 
1.14(1.01-1.29) 
- 
- 
- 
0.023 
0.018 
- 
- 
<0.001 
- 
0.041 
- 
- 
- 
  
Model 2. Considering appropriateness of empirical antibiotic therapy 
 
Infection (at ACLF diagnosis or during follow-up)    
Appropriate empirical antibiotic therapy 
Age (years) 
Encephalopathy (%)* 
Leukocytes (x109/L)* 
Bilirubin (mg/dL)* 
INR* 
Creatinine (mg/dL)* 
Heart rate (b.p.m)* 
Mechanical ventilation** 
Renal replacement therapy** 
1.65(1.05-2.60) 
0.41(0.27-0.62) 
1.01(0.99-1.03) 
1.56(1.03-2.37) 
1.07(1.04-1.11) 
1.02(1.01-1.04) 
1.11(0.91-1.36) 
1.12(0.98-1.28) 
1.02(1.01-1.03) 
2.55(1.62-4.01) 
2.32(1.51-3.57) 
0.031 
<0.001 
0.147 
0.036 
<0.001 
0.007 
0.299 
0.098 
0.001 
<0.001 
<0.001 
 1.99(0.65-6.10) 
0.40(0.26-0.63) 
1.02(1.00-1.04) 
- 
- 
1.03(1.01-1.05) 
- 
- 
- 
- 
- 
0.228 
<0.001 
0.037 
- 
- 
0.009 
- 
- 
- 
- 
- 
* At ACLF diagnosis; ** Within the 4-weeks follow-up period 
 #Mechanical ventilation and leukocytes were not included in the multivariate model because of potential collinearity with infection 
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